PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Klimek, L.* ; Kündig, T.* ; Kramer, M.F.* ; Guethoff, S.* ; Jensen-Jarolim, E.* ; Schmidt-Weber, C.B. ; Palomares, O.* ; Mohsen, M.O.* ; Jakob, T.* ; Bachmann, M.*

Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases.

Allergo J. Int. 27, 245-255 (2018)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Background: Apart from active allergen avoidance, immunotherapy is regarded as the most effective form of treatment available for type I allergies. Such treatments involve the administration of allergen preparations in various forms and by various routes. Virus-like particles (VLPs) offer a very effective platform for immunization with the allergen and are characterized by high immunogenicity, low allergenicity and high clinical efficacy. Formulations that include Toll-like receptor ligands, T cell stimulatory epitopes and/or depot-forming adjuvants appear to enhance activation of the relevant immune cells. Short nucleotide sequences including CpG motifs have also been intensively explored as potent stimulators of dendritic cells and B cells. Methods: The present paper is based on a systematic literature search in PubMed and MEDLINE, and focuses on the pertinent immunological processes and on clinical data relating to use of VLPs and CpG motifs for the treatment of allergic rhinitis (AR). Results: Many published studies have reported positive clinical results following administration of VLPs, either alone or in combination with CpG motifs and, in some cases, even in the absence of the allergen-specific allergen. Conclusions: These results indicate that VLPs modulate immune responses in ways which underline their exceptional promise as a platform for the immunotherapy of allergic disorders. However, clinical evaluations remain limited, and further large-scale and longer-term studies will be necessary to substantiate the efficacy and safety of these novel therapies.
Impact Factor
Scopus SNIP
Scopus
Cited By
Altmetric
0.000
0.000
22
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Adjuvants ; Allergic Rhinitis ; Allergy ; Cpg Motifs ; Immunotherapy ; Vaccines ; Virus-like Particles
Sprache englisch
Veröffentlichungsjahr 2018
HGF-Berichtsjahr 2018
ISSN (print) / ISBN 2197-0378
e-ISSN 2197-0378
Zeitschrift Allergo Journal International
Quellenangaben Band: 27, Heft: 8, Seiten: 245-255 Artikelnummer: , Supplement: ,
Verlag Urban & Vogel
Verlagsort München
Begutachtungsstatus Peer reviewed
Institut(e) Institute for Allergy Research (IAF)
POF Topic(s) 30202 - Environmental Health
Forschungsfeld(er) Allergy
PSP-Element(e) G-505400-001
DOI 10.1007/s40629-018-0074-y
Scopus ID 85051057677
PubMed ID 30546996
Erfassungsdatum 2018-09-14
[➜Korrektur melden]